Rakovina Therapeutics to Present New Data Highlighting Novel ATR Inhibitor with CNS Penetration at the AACR-NCI-EORTC International Conference

VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV, FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today announced that new preclinical data from its ATR inhibitor program will be presented in a poster session at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 22-26 at the Hynes Convention Center Boston, Massachusetts.